List of Excipients in Branded Drug ADVIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	ACESULFAME POTASSIUM
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	CARAMEL
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	CARNAUBA WAX
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	COPOVIDONE K25-31
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	FERRIC OXIDE RED
Haleon US Holdings LLC	ADVIL	ibuprofen sodium	0573-0133	HYPROMELLOSE

Advil Excipient Strategy, Formulation Opportunities, and Commercial Outlook

Last updated: August 26, 2026

Advil is an ibuprofen-based over-the-counter product with limited protection from active-ingredient patents and no biologic or biosimilar barrier. Its commercial value depends on formulation performance, dosage-form convenience, brand recognition, regulatory compliance, manufacturing reliability, and retail distribution. The strongest excipient opportunities are in rapid-release tablets, soft gelatin capsules, pediatric liquids, combination products, taste masking, sugar reduction, and sustainable packaging and dosage technologies.

What is the regulatory status of Advil and ibuprofen?

Advil contains ibuprofen, a nonsteroidal anti-inflammatory drug used for temporary relief of minor aches and pains and reduction of fever. Standard adult Advil products generally contain 200 mg of ibuprofen per dosage unit.

In the United States, ibuprofen is regulated primarily under the FDA’s OTC monograph framework for internal analgesic, antipyretic, and antirheumatic products. The applicable requirements are set out in 21 C.F.R. Part 343. A conforming product can be marketed without a product-specific new drug application if it satisfies the monograph’s active-ingredient, dosage, labeling, and manufacturing requirements.[1]

Regulatory item	Advil and ibuprofen position
Active ingredient	Ibuprofen
Common strength	200 mg per tablet, capsule, or liqui-gel
U.S. pathway	OTC monograph or approved OTC application, depending on product
Primary FDA category	Internal analgesic, antipyretic, and antirheumatic
Prescription requirement	No for standard OTC Advil products
Biosimilar pathway	Not applicable
Orange Book relevance	Limited for monograph-compliant OTC products
Main regulatory constraints	Dosage, warnings, labeling, quality, dissolution, manufacturing, and excipient compliance

FDA’s OTC monograph order system replaced the former monograph format for many categories, but the commercial effect remains similar: a company does not receive broad exclusivity merely by complying with the monograph.[2]

What excipients are used in Advil formulations?

Advil excipients vary by dosage form, product line, market, strength, and manufacturing site. The formulation strategy generally separates into compressed tablets, soft gelatin liquid-filled capsules, pediatric liquids, and combination products.

Advil coated tablets

Representative inactive ingredients disclosed in U.S. labeling for ibuprofen tablets include:

• Microcrystalline cellulose
• Corn starch
• Croscarmellose sodium
• Colloidal silicon dioxide
• Hypromellose
• Lactose monohydrate
• Magnesium stearate
• Povidone
• Sodium lauryl sulfate
• Talc
• Titanium dioxide
• Pharmaceutical glaze

These excipients support several technical functions:

Excipient function	Typical formulation role
Diluent	Adds bulk and improves tablet compression
Disintegrant	Promotes tablet breakup after ingestion
Binder	Improves granule and tablet strength
Glidant	Improves powder flow during manufacturing
Lubricant	Reduces ejection force and tooling adhesion
Film former	Protects the tablet and improves appearance
Surfactant	Improves wetting and dissolution
Opacifier or colorant	Controls appearance and light protection

A key formulation objective is to obtain rapid disintegration and dissolution without compromising mechanical strength. Ibuprofen has relatively low aqueous solubility, so the excipient system must manage wetting, particle dispersion, compression, and dissolution rather than simply increase tablet hardness.

Advil Liqui-Gels and soft gelatin capsules

Liqui-Gel products use a soft gelatin shell and a liquid or semisolid fill. Representative shell and fill materials may include:

• Gelatin
• Sorbitol or other plasticizers
• Purified water
• Polyethylene glycol
• Mineral oil or other fill vehicle
• Lecithin
• Potassium hydroxide
• Pharmaceutical ink
• Colorants or opacifiers

The commercial proposition is faster swallowing and a differentiated dosage form. The technical challenges include shell compatibility, fill migration, ibuprofen solubilization or dispersion, oxidative stability, gelatin cross-linking, seal integrity, and dissolution after storage.

Softgel manufacturing also creates a higher barrier to entry than conventional tablet compression. A competitor needs capsule machinery, controlled encapsulation parameters, specialized in-process testing, and validated shell-fill compatibility.

Advil Children’s products

Pediatric Advil products are commonly supplied as oral suspensions. Excipients in pediatric liquids may include:

• Purified water
• Suspending agents
• Sweeteners
• Flavor systems
• Buffers
• Preservatives
• Wetting agents
• Viscosity modifiers
• Colorants

The commercial requirements differ from adult tablets. Dose-measurement accuracy, taste masking, physical stability, pourability, preservative performance, and caregiver usability determine product competitiveness.

A pediatric liquid can lose commercial value if the suspension settles rapidly, forms a difficult-to-redisperse cake, foams during shaking, or has a strong ibuprofen aftertaste. Excipient suppliers can create value through low-sugar systems, preservative-reduced systems, improved flavor masking, and suspensions with more consistent dosing over the labeled shelf life.

What formulations are protected by Advil patents?

Advil’s core commercial products are unlikely to receive meaningful current protection from the original ibuprofen composition or standard oral dosage-form concepts. Ibuprofen has been marketed for decades, and broad active-ingredient and conventional tablet claims have generally expired.

The current protection profile is more likely to involve:

• Trademarks covering Advil and product names
• Trade dress and packaging
• Product-specific formulation patents, if active
• Manufacturing know-how
• Softgel process controls
• Supplier relationships
• Flavor and sensory systems
• Regulatory and quality documentation
• Retail distribution and brand investment

No reliable conclusion should be drawn that a specific Advil formulation is patent-free solely because ibuprofen is an old active ingredient. A product-by-product review must examine U.S. patent records, foreign filings, assignment data, terminal disclaimers, maintenance fees, and litigation history.

When does Advil lose exclusivity?

Advil does not have a single patent-exclusivity expiration date comparable to a recently approved prescription medicine.

Patent exclusivity

The original ibuprofen patents expired decades ago. Conventional 200 mg ibuprofen tablets and capsules can be developed by competitors subject to applicable FDA requirements, labeling rules, quality standards, and trademark restrictions.

Regulatory exclusivity

Standard OTC monograph-compliant ibuprofen products generally do not receive the five-year or three-year exclusivity periods associated with certain new prescription or OTC applications. A novel approved OTC formulation could create a separate regulatory position, but the scope would depend on the application, approval basis, and any listed patents.

Brand exclusivity

Advil retains commercial exclusivity through brand equity rather than active-ingredient exclusivity. Retail shelf placement, consumer recognition, advertising, perceived speed of relief, dosage-form familiarity, and portfolio breadth are the principal barriers.

Does Advil have Orange Book listings or Paragraph IV challenges?

The Orange Book is primarily relevant to approved prescription and certain approved nonprescription drug applications. A standard monograph product does not create the same Orange Book patent-certification framework as an approved NDA product.

As a result, the typical Paragraph IV pathway is not the main competitive mechanism for a monograph-compliant Advil equivalent. A competitor can generally commercialize an ibuprofen OTC product by complying with the applicable monograph, submitting required FDA materials where applicable, and avoiding infringement of enforceable formulation or process claims.

The practical legal risks are more likely to involve:

• Trademark infringement
• False or misleading comparative advertising
• Trade dress claims
• Product-specific formulation patents
• Manufacturing-process patents
• Packaging and labeling disputes
• State consumer-protection claims

Which companies compete with Advil?

The principal competition comes from both branded and private-label ibuprofen products.

Competitor category	Examples	Competitive basis
Branded ibuprofen	Motrin, generic store brands under retailer labels	Brand recognition and distribution
Retailer private label	CVS, Walgreens, Walmart, Costco and other store brands	Lower price and equivalent active ingredient
Combination analgesics	Products combining ibuprofen with acetaminophen or other actives	Broader pain positioning
Aspirin and naproxen	Bayer, Aleve and private-label products	Longer duration or different consumer preference
Acetaminophen	Tylenol and store brands	Different safety and use profile
Specialty delivery forms	Softgels, caplets, chewables and liquids	Convenience, swallowing, taste and perceived onset

The strongest direct threat is private-label ibuprofen. Private-label manufacturers can use the same active ingredient and many of the same excipients while selling at materially lower prices. Advil must therefore differentiate through dosage form, packaging, consumer trust, and product claims that are supported by evidence.

What excipient strategies create commercial opportunities?

1. Rapid-release ibuprofen tablets

A rapid-release platform could combine:

• Micronized ibuprofen
• Wetting agents
• Superdisintegrants
• Porous or co-processed fillers
• Low-lubricant formulations
• Optimized particle-size distribution
• Controlled tablet hardness

The commercial opportunity is a credible faster-onset positioning supported by dissolution data and, where needed, clinical pharmacokinetic or onset data. The principal risk is that faster in vitro dissolution does not automatically establish faster clinical pain relief.

2. Improved softgel fills

Softgel products can be optimized using:

• Solubilizing vehicles
• Polyethylene glycol systems
• Lipid-based dispersions
• Surfactant combinations
• Antioxidants
• Lower-viscosity fills
• Shell formulations with better moisture control

The objectives are improved content uniformity, fill stability, leakage resistance, dissolution, and manufacturing yield. A formulation that reduces shell brittleness and gelatin cross-linking can generate value even without a consumer-facing claim.

3. Pediatric taste masking

Pediatric ibuprofen has a persistent bitterness problem. Commercially relevant technologies include:

• Ion-exchange resin complexes
• Polymer coating
• Lipid coating
• Flavor-layered particles
• Encapsulation
• Sweetener combinations
• Reduced-aftertaste flavor systems
• pH-controlled suspension vehicles

A taste-masked product may support premium pricing, improve adherence, and reduce caregiver resistance. Any change must preserve dose uniformity, redispersibility, preservative efficacy, and release performance.

4. Sugar-free and low-calorie liquids

A sugar-free suspension can target consumers seeking reduced sugar intake. The formulation must control:

• Sweetener intensity
• Cooling or metallic aftertaste
• Viscosity
• Sedimentation
• Pourability
• Microbial protection
• Compatibility with dosing syringes

Polyols and high-intensity sweeteners can improve sugar reduction but may introduce gastrointestinal tolerability, osmolarity, or sensory issues.

5. Low-dust and direct-compression systems

Co-processed excipients can simplify manufacturing by improving flow, compaction, and blend uniformity. A direct-compression ibuprofen platform could reduce granulation steps, energy use, and processing time.

The technical challenge is ibuprofen’s high dose relative to many excipient systems. The formulation must maintain tablet strength and dissolution while preventing sticking, picking, segregation, and weight variation.

6. Sodium-conscious formulations

Consumers increasingly scrutinize sodium content in OTC products. An ibuprofen product can be positioned with a low-sodium excipient system, although the active ingredient and full formulation must be evaluated rather than relying on a single excipient substitution.

7. Sustainable excipient and capsule systems

Commercial opportunities include:

• Plant-derived capsule shells
• Reduced titanium dioxide systems where permitted
• Lower-impact colorants
• Bio-based plasticizers
• Reduced-solvent coating processes
• Lower-material packaging
• Recyclable blister structures

Sustainability claims require substantiation and must not compromise moisture protection, child resistance, shelf life, or product integrity.

How strong is the Advil patent estate?

The core patent estate is weak as a barrier to generic ibuprofen. The commercial estate is stronger than the active-ingredient estate because it combines trademark rights, consumer recognition, manufacturing scale, packaging, retailer relationships, and product-line extensions.

Estate component	Relative barrier
Ibuprofen active ingredient	Low
Conventional 200 mg tablet	Low
Standard excipient combination	Low to moderate
Proprietary rapid-release formulation	Moderate, if claims remain enforceable
Softgel manufacturing process	Moderate
Pediatric taste-masking system	Moderate to high, depending on claims
Brand and trade dress	Moderate
Retail distribution	High for smaller entrants
Manufacturing scale	Moderate to high

Patent strength depends on claim specificity. A narrow claim covering a particular ibuprofen particle size, solvent system, shell composition, or taste-masking process may be enforceable but easier to design around than a broad composition claim.

What generic launch scenarios exist for Advil?

Low-cost conventional tablet launch

This is the easiest entry route. A manufacturer can produce 200 mg ibuprofen tablets using conventional excipients and compete primarily on price. The main risks are manufacturing scale, retailer access, quality consistency, and compliance with FDA labeling.

Premium softgel launch

A competitor can enter with a liquid-filled capsule or liqui-gel. The formulation and manufacturing barrier is higher, but the product may support better margins and differentiation.

Pediatric formulation launch

A taste-masked, sugar-free, low-viscosity, or improved-measurement pediatric suspension can compete on caregiver experience rather than price.

Combination-product launch

Ibuprofen-acetaminophen products can create a broader pain-relief proposition. These products carry more complicated labeling, interaction, dosing, and safety considerations than single-ingredient ibuprofen.

Private-label substitution

Retailers can replace branded Advil units with lower-cost ibuprofen products, particularly in price-sensitive channels. This is the most direct revenue risk to the brand.

What revenue exposure does Advil face?

Advil revenue is exposed to four main factors:

1. Private-label price competition.
2. Consumer migration to acetaminophen, naproxen, or combination products.
3. Retailer bargaining power and shelf allocation.
4. Regulatory or safety-related changes affecting NSAID use.

A branded product can defend revenue through premium dosage forms, pediatric products, convenience packaging, multipacks, and strong consumer communications. The commercial opportunity is limited if the product remains a standard 200 mg tablet with no meaningful user benefit beyond the brand name.

What manufacturing and IP barriers affect new Advil competitors?

The active ingredient is broadly available from generic pharmaceutical suppliers. The more meaningful barriers are operational:

• Consistent ibuprofen particle-size control
• Blend uniformity at high active loading
• Tablet sticking and picking
• Dissolution control
• Softgel encapsulation capability
• Gelatin-shell stability
• Suspension redispersibility
• Taste-masking reproducibility
• Packaging moisture protection
• Stability data across climate zones
• FDA-compliant quality systems

A new entrant should prioritize excipient compatibility studies early. Common failure points include lubricant overuse, slowed dissolution, shell-fill migration, preservative loss, flavor instability, and changes in suspension viscosity during storage.

What licensing opportunities exist around Advil formulations?

There is no obvious need to license the basic ibuprofen active ingredient. Licensing value is more likely in enabling technologies:

• Rapid-release ibuprofen particles
• Taste-masked pediatric ibuprofen
• Novel softgel fill systems
• Plant-based capsule shells
• Co-processed direct-compression excipients
• Low-sugar suspension platforms
• Child-resistant unit-dose packaging
• Stability-enhancing blister systems

A licensing deal would be most defensible where the technology produces measurable advantages in dissolution, sensory performance, shelf life, manufacturing yield, or consumer adherence. A generic excipient substitution without a measurable product benefit is unlikely to justify material royalty economics.

Key Takeaways

• Advil’s active ingredient, ibuprofen, has little remaining patent-based exclusivity.
• Standard OTC ibuprofen products generally compete under FDA monograph requirements rather than Paragraph IV litigation.
• The Orange Book is less central to conventional Advil-equivalent products than it is to prescription NDA products.
• The strongest commercial barriers are brand, retail distribution, formulation know-how, manufacturing scale, and consumer trust.
• Excipient opportunities are concentrated in rapid release, softgel stability, pediatric taste masking, sugar reduction, direct compression, and sustainable dosage forms.
• Private-label ibuprofen is the principal direct threat to Advil’s pricing and market share.
• A new formulation needs measurable performance advantages to support premium pricing or licensing value.
• Softgels and pediatric suspensions create higher technical barriers than conventional tablets.
• Manufacturing-process control can be as commercially important as patent protection in mature OTC analgesics.

FAQs About Advil Excipients and Commercial Strategy

Can a company sell an ibuprofen tablet with the same excipients as Advil?

Yes, provided the product complies with applicable FDA requirements and does not infringe enforceable formulation, process, trademark, or trade-dress rights.

Is Advil protected by a patent on its 200 mg ibuprofen tablet?

The original ibuprofen and conventional tablet concepts are not meaningful current barriers. Any relevant protection would need to arise from a specific formulation, process, or product-specific patent.

Are Advil Liqui-Gels harder to copy than Advil tablets?

Yes. Softgel products require specialized shell and fill technology, compatibility testing, encapsulation equipment, and stability controls. The barrier is operational and technical, not necessarily broad patent exclusivity.

What is the best excipient opportunity for pediatric ibuprofen?

Taste masking combined with a stable, sugar-reduced suspension is among the strongest opportunities because it addresses adherence and caregiver usability while creating differentiation from low-cost generic liquids.

Can excipients support a faster-acting Advil product claim?

They can improve wetting, disintegration, and dissolution, but a faster-acting claim requires appropriate substantiation. In vitro dissolution alone may not establish faster clinical pain relief.

References

1. Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. U.S. Government Publishing Office.

2. U.S. Food and Drug Administration. (2024). OTC monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines/otc-monograph-drugs

3. U.S. Food and Drug Administration. (2024). DailyMed: Ibuprofen tablet and capsule labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

5. Haleon plc. (2024). Annual report and financial statements. https://www.haleon.com/investors/results-centre/annual-reports/